Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Troels Holz Borch

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|May 30, 2016
Immune Monitoring Using mRNA-Transfected Dendritic CellsTroels Holz Borch, Inge Marie Svane, Özcan Met
Muscle & Nerve|May 19, 2021
Metastatic melanoma presenting with subacute sensory neuronopathySonja Holm-Yildiz, Clarissa Crone, Troels Holz Borch, et al.
Cancer Immunology, Immunotherapy : CII|January 4, 2016
PD-L1-specific T cellsShamaila Munir Ahmad, Troels Holz Borch, Morten Hansen, et al.
Melanoma Research|April 2, 2025
Steroid-refractory severe immune-related mucositis following adjuvant anti-PD-1 therapy for resectable melanoma: a case reportSidsel Pedersen, Troels Holz Borch, Inge Marie Svane, et al.
American Journal of Clinical Dermatology|July 16, 2025
The Challenge of Treating Anti-PD-1-Resistant Advanced MelanomaCecilie Dam Vestergaard, Eva Ellebaek, Troels Holz Borch, et al.
Journal for Immunotherapy of Cancer|August 5, 2020
Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanomaTroels Holz Borch, Rikke Andersen, Eva Ellebaek, et al.
Cytotherapy|May 2, 2021
Bone marrow toxicity and immune reconstitution in melanoma and non-melanoma solid cancer patients after non-myeloablative conditioning with chemotherapy and checkpoint inhibitionAnders H Kverneland, Troels Holz Borch, Joachim Granhøj, et al.
Journal for Immunotherapy of Cancer|February 6, 2025
Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytesTroels Holz Borch, Rikke Andersen, Helle Westergren Hendel, et al.
Cancer Immunology, Immunotherapy : CII|March 10, 2018
Cancer immunotherapy in patients with brain metastasesSalvatore Caponnetto, Arianna Draghi, Troels Holz Borch, et al.
Journal for Immunotherapy of Cancer|March 14, 2024
Biomarkers for response to TIL therapy: a comprehensive reviewVíctor Albarrán Fernández, Pablo Ballestín Martínez, Joachim Stoltenborg Granhøj, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Methods in Molecular Biology (Clifton, N.J.)|May 30, 2016
Immune Monitoring Using mRNA-Transfected Dendritic CellsTroels Holz Borch, Inge Marie Svane, Özcan Met
Muscle & Nerve|May 19, 2021
Metastatic melanoma presenting with subacute sensory neuronopathySonja Holm-Yildiz, Clarissa Crone, Troels Holz Borch, et al.
Cancer Immunology, Immunotherapy : CII|January 4, 2016
PD-L1-specific T cellsShamaila Munir Ahmad, Troels Holz Borch, Morten Hansen, et al.
Melanoma Research|April 2, 2025
Steroid-refractory severe immune-related mucositis following adjuvant anti-PD-1 therapy for resectable melanoma: a case reportSidsel Pedersen, Troels Holz Borch, Inge Marie Svane, et al.
American Journal of Clinical Dermatology|July 16, 2025
The Challenge of Treating Anti-PD-1-Resistant Advanced MelanomaCecilie Dam Vestergaard, Eva Ellebaek, Troels Holz Borch, et al.
Journal for Immunotherapy of Cancer|August 5, 2020
Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanomaTroels Holz Borch, Rikke Andersen, Eva Ellebaek, et al.
Cytotherapy|May 2, 2021
Bone marrow toxicity and immune reconstitution in melanoma and non-melanoma solid cancer patients after non-myeloablative conditioning with chemotherapy and checkpoint inhibitionAnders H Kverneland, Troels Holz Borch, Joachim Granhøj, et al.
Journal for Immunotherapy of Cancer|February 6, 2025
Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytesTroels Holz Borch, Rikke Andersen, Helle Westergren Hendel, et al.
Cancer Immunology, Immunotherapy : CII|March 10, 2018
Cancer immunotherapy in patients with brain metastasesSalvatore Caponnetto, Arianna Draghi, Troels Holz Borch, et al.
Journal for Immunotherapy of Cancer|March 14, 2024
Biomarkers for response to TIL therapy: a comprehensive reviewVíctor Albarrán Fernández, Pablo Ballestín Martínez, Joachim Stoltenborg Granhøj, et al.
Pageof 3